Wall Street analysts forecast that Cellectis SA (NASDAQ:CLLS) will post sales of $9.43 million for the current quarter, Zacks reports. Three analysts have made estimates for Cellectis’ earnings, with the lowest sales estimate coming in at $7.60 million and the highest estimate coming in at $10.69 million. Cellectis reported sales of $8.96 million in the same quarter last year, which would suggest a positive year over year growth rate of 5.2%. The firm is expected to issue its next earnings report on Wednesday, August 1st.
On average, analysts expect that Cellectis will report full-year sales of $36.10 million for the current year, with estimates ranging from $31.30 million to $41.98 million. For the next financial year, analysts forecast that the firm will report sales of $47.77 million per share, with estimates ranging from $32.00 million to $77.10 million. Zacks’ sales averages are an average based on a survey of sell-side research analysts that follow Cellectis.
Cellectis (NASDAQ:CLLS) last posted its quarterly earnings results on Monday, May 7th. The biotechnology company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.01). The business had revenue of $8.07 million during the quarter, compared to the consensus estimate of $9.53 million. Cellectis had a negative return on equity of 37.45% and a negative net margin of 337.45%.
Several equities analysts have recently commented on the stock. BidaskClub downgraded shares of Cellectis from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, March 14th. Nomura upped their price objective on shares of Cellectis to $73.00 and gave the company a “buy” rating in a research note on Wednesday, March 14th. Guggenheim began coverage on shares of Cellectis in a research note on Friday, March 16th. They set a “neutral” rating for the company. ValuEngine upgraded shares of Cellectis from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Finally, Oppenheimer boosted their price target on shares of Cellectis from $40.00 to $44.00 and gave the company an “outperform” rating in a research report on Tuesday, June 12th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $42.67.
Shares of Cellectis traded down $0.66, hitting $28.46, during midday trading on Friday, Marketbeat reports. 99,787 shares of the stock traded hands, compared to its average volume of 247,122. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -10.24 and a beta of 1.88. Cellectis has a one year low of $21.25 and a one year high of $38.85.
A number of institutional investors and hedge funds have recently made changes to their positions in CLLS. Perceptive Advisors LLC purchased a new stake in Cellectis in the fourth quarter worth about $10,203,000. Nexthera Capital LP purchased a new stake in shares of Cellectis during the first quarter valued at approximately $10,485,000. BlackRock Inc. purchased a new stake in shares of Cellectis during the fourth quarter valued at approximately $4,422,000. Bain Capital Public Equity Management LLC bought a new position in Cellectis during the fourth quarter valued at approximately $2,848,000. Finally, Millennium Management LLC lifted its position in Cellectis by 1,356.2% during the fourth quarter. Millennium Management LLC now owns 104,290 shares of the biotechnology company’s stock valued at $3,040,000 after purchasing an additional 97,128 shares during the period. Institutional investors and hedge funds own 16.76% of the company’s stock.
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
Get a free copy of the Zacks research report on Cellectis (CLLS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.